Analysts expect BioScrip Inc (NASDAQ:BIOS) to post ($0.12) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for BioScrip’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.14). BioScrip also reported earnings of ($0.12) per share in the same quarter last year. The company is expected to announce its next quarterly earnings results on Thursday, May 9th.
On average, analysts expect that BioScrip will report full-year earnings of ($0.25) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.14). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.19) per share, with EPS estimates ranging from ($0.21) to ($0.17). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow BioScrip.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Friday, March 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.11). The firm had revenue of $183.57 million for the quarter, compared to analyst estimates of $188.39 million. The business’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter last year, the business earned ($0.03) earnings per share.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in shares of BioScrip by 0.4% in the third quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock valued at $23,610,000 after purchasing an additional 31,899 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of BioScrip by 24.2% in the third quarter. Dimensional Fund Advisors LP now owns 2,436,632 shares of the company’s stock valued at $7,554,000 after purchasing an additional 474,126 shares in the last quarter. Citadel Advisors LLC lifted its holdings in shares of BioScrip by 471.9% in the third quarter. Citadel Advisors LLC now owns 66,502 shares of the company’s stock valued at $206,000 after purchasing an additional 54,874 shares in the last quarter. Venor Capital Management LP lifted its holdings in shares of BioScrip by 0.3% in the third quarter. Venor Capital Management LP now owns 14,475,087 shares of the company’s stock valued at $44,873,000 after purchasing an additional 50,000 shares in the last quarter. Finally, MetLife Investment Advisors LLC lifted its holdings in shares of BioScrip by 51.6% in the third quarter. MetLife Investment Advisors LLC now owns 98,122 shares of the company’s stock valued at $304,000 after purchasing an additional 33,395 shares in the last quarter. Institutional investors own 82.40% of the company’s stock.
Shares of BioScrip stock traded down $0.01 on Friday, reaching $1.76. The company had a trading volume of 39,119 shares, compared to its average volume of 2,054,197. The company has a market capitalization of $225.54 million, a price-to-earnings ratio of -3.58 and a beta of 0.69. BioScrip has a 52-week low of $1.69 and a 52-week high of $4.14.
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
See Also: Why is the ROA ratio important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.